REC 02Alternative Names: REC-02
Latest Information Update: 08 Jan 2016
At a glance
- Originator RECARDIO
- Class Heart failure therapies
- Mechanism of Action Chemokine CXCL12 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Heart failure
Most Recent Events
- 08 Jan 2016 Phase-I clinical trials in Heart failure in Austria (unspecified route)